225 related articles for article (PubMed ID: 19530514)
1. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?
Manna R; Verrecchia E; Fonnesu C; Giovinale M; De Socio G; Curigliano V; Cerquaglia C; Soriano A; Granata M; Migliore A; Massafra U; Gasbarrini G
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():63-9. PubMed ID: 19530514
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study.
Guitard J; Sandres-Sauné K; Kamar N; Ribes D; Faguer S; Esposito L; Lavit M; Muscari F; Péron JM; Lavayssière L; Durand D; Rostaing L
Transplant Proc; 2007 Oct; 39(8):2603-5. PubMed ID: 17954189
[TBL] [Abstract][Full Text] [Related]
3. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.
Galeazzi M; Bellisai F; Giannitti C; Manganelli S; Morozzi G; Sebastiani GD
Ann N Y Acad Sci; 2007 Sep; 1110():544-9. PubMed ID: 17911470
[TBL] [Abstract][Full Text] [Related]
4. Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients.
Thiele DL; DuCharme L; Cunningham MR; Mimms LT; Cuthbert JA; Lee WM; Combes B
Am J Gastroenterol; 1996 Feb; 91(2):300-8. PubMed ID: 8607497
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy.
Nanmoku K; Imaizumi R; Tojimbara T; Nakajima I; Fuchinoue S; Sakamoto N; Watanabe M; Teraoka S
Transplant Proc; 2008 Sep; 40(7):2382-5. PubMed ID: 18790241
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients.
Galeazzi M; Bellisai F; Manganelli S; Morozzi G; Sebastiani GD
Autoimmun Rev; 2006 Aug; 5(7):493-8. PubMed ID: 16920576
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
[TBL] [Abstract][Full Text] [Related]
8. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome.
Schiano TD; Te HS; Thomas RM; Hussain H; Bond K; Black M
Am J Gastroenterol; 2001 Oct; 96(10):2984-91. PubMed ID: 11693337
[TBL] [Abstract][Full Text] [Related]
9. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
[TBL] [Abstract][Full Text] [Related]
10. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
Watashi K; Shimotohno K
Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
[TBL] [Abstract][Full Text] [Related]
11. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
[TBL] [Abstract][Full Text] [Related]
12. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
Cavazzana I; Ceribelli A; Cattaneo R; Franceschini F
Autoimmun Rev; 2008 Dec; 8(2):104-6. PubMed ID: 19014870
[TBL] [Abstract][Full Text] [Related]
13. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
[TBL] [Abstract][Full Text] [Related]
14. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
Watashi K
Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of non infectious ocular inflammatory disease with low doses of cyclosporin A].
Cuchacovich M; Gatica H; Verdaguer JI; Carreño MA; Villarroel F; Verdaguer J
Rev Med Chil; 1999 Mar; 127(3):277-85. PubMed ID: 10436711
[TBL] [Abstract][Full Text] [Related]
16. Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
Muzi F; Orlando G; Ielpo B; Anselmo A; Sabato Ceraldi S; de Liguori Carino N; Manzia T; D'Andria D; Tariciotti L; Angelico M; Tisone G
Transplant Proc; 2005 May; 37(4):1705-7. PubMed ID: 15919438
[TBL] [Abstract][Full Text] [Related]
17. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
Tisone G; Orlando G; Cardillo A; Palmieri G; Manzia TM; Baiocchi L; Lionetti R; Anselmo A; Toti L; Angelico M
J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433
[TBL] [Abstract][Full Text] [Related]
18. [IFN combined cyclosporin A therapy].
Inoue K; Yoshiba M
Nihon Rinsho; 2001 Jul; 59(7):1326-30. PubMed ID: 11494546
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
Oton E; Barcena R; Castillo M; Barreales M; Blesa C; Moreno-Planas JM; Barrios C; Garrido A; Cuervas V
Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus infection and haemodialysis: experience of a district general hospital in Brunei Darussalam.
Chong VH; Zinna HS
Singapore Med J; 2008 Nov; 49(11):916-20. PubMed ID: 19037559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
